WC
ALXN

Wexford Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Wexford Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-2,900
Closed -$353K – 205
2017
Q2 		$353K Buy
+2,900
New +$338K 0.03% 135
2015
Q2 		– Sell
-14,515
Closed -$2.52M – 80
2015
Q1 		$2.52M Buy
+14,515
New +$2.63M 0.73% 26
2013
Q3 		– Sell
-86,800
Closed -$8.01M – 272
2013
Q2 		$8.01M Buy
+86,800
New +$8.36M 0.7% 24

Other funds holding ALXN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Wexford Capital's ALXN Position: Q3 2017 in Review

Wexford Capital sold out of Alexion Pharmaceuticals (ALXN) in Q3 2017, closing a stake of 2,900 shares — an estimated $353K sold.

Wexford Capital first reported a position in ALXN in Q2 2013 and held it in 3 quarters. The position peaked at $8.01M in Q2 2013. 595 funds tracked by Wall St. Rank hold ALXN as of Q3 2017.

  • Wexford Capital reported no remaining Alexion Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Wexford Capital sold 2,900 Alexion Pharmaceuticals shares in Q3 2017, an estimated $353K.
  • Wexford Capital first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Wexford Capital's Alexion Pharmaceuticals position peaked at $8.01M in Q2 2013.
  • 595 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2017.

Based on Wexford Capital's 13F filing for Q3 2017, filed 13 Nov 2017.